Is there a drug company on the planet more screwed up than Genzyme right now? (Possibly, but it's a tight contest.) Here's what's happening at the maker of Cerezyme, the only treatment for Gaucher ...

Here's how crazy CEO incentive compensation is: Genzyme (GENZ) CEO Henri Termeer walked away from his company with a payout that may be worth $300 million yesterday when Sanofi-Aventis (SNY) acquired ...

French drug maker Sanofi SA had hoped Genzyme Corp.’s high-profile production problems would be quickly put to rest when it acquired the Cambridge company. But five months after Sanofi completed its ...

Cambridge biotech Genzyme has priced its new pill to treat Gaucher disease at $310,250 a year for the small population of US patients suffering from the rare genetic disorder. The price — listed as ...

CAMBRIDGE, Mass. and SOUTH PLAINFIELD, N.J., July 17 /PRNewswire- FirstCall/ -- Genzyme Corporation (Nasdaq: GENZ) and PTC Therapeutics, Inc. (PTC) today announced an exclusive global collaboration to ...

Shares of Alnylam Pharmaceuticals Inc. soared to an all-time high price Monday after the drug developer said it will receive a $700 million investment from the Genzyme unit of French pharmaceutical ...

Genzyme is stepping up its presence in the currently hot oncology world by extending relationships with Bayer Healthcare for three drugs compounds. The deal between the two biotech companies will ...

PARIS/BOSTON (Reuters) - Biotech company Genzyme Inc rejected an $18.5 billion buyout offer from French drugmaker Sanofi-Aventis SA on Monday, setting the stage for a protracted and potentially ...

French drugmaker Sanofi-Aventis launched a hostile bid for Genzyme at $69 per share, or $18.5 billion, setting off what could be a protracted battle for control of the U.S. biotech company. The move ...

Genzyme and Isis Pharmaceuticals announced today that they have entered a major strategic alliance in which Genzyme will develop and commercialize mipomersen, Isis’ lipid-lowering treatment for high ...

Sanofi-Aventis of France took its $18.5 billion takeover bid for Genzyme hostile on Monday, going directly to Genzyme’s shareholders in an effort to advance deal negotiations. Sanofi declined to raise ...

Sanofi-Aventis, the French drug maker, publicly disclosed its $18.5 billion bid for Genzyme on Sunday, intensifying pressure on the American biotechnology company to engage in discussions about a sale ...